<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04347720</url>
  </required_header>
  <id_info>
    <org_study_id>1025627</org_study_id>
    <nct_id>NCT04347720</nct_id>
  </id_info>
  <brief_title>Canadian National PDA Treatment Study</brief_title>
  <acronym>CANRxPDA</acronym>
  <official_title>Relative Effectiveness and Safety of Pharmacotherapeutic Agents for Patent Ductus Arteriosus (PDA) in Preterm Infants: A National Comparative Effectiveness Research (CER) Project</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IWK Health Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Provincial Health Services Authority</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of Eastern Ontario</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CHU de Quebec-Universite Laval</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Foothills Medical Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Victoria General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Health Sciences Centre, Winnipeg, Manitoba</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Justine's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kingston Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MOUNT SINAI HOSPITAL</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Alexandra Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Regina General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal University Hospital Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Boniface General Hospital Research Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Moncton Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Horizon Health Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Windsor Regional Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Columbian Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>London Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IWK Health Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patent ductus arteriosus (PDA) is the most common cardiovascular problem that develops in
      preterm infants. Persistent PDA may result in higher rates of death, chronic lung disease
      (CLD), pulmonary hemorrhage, necrotizing enterocolitis (NEC), acute kidney injury (AKI),
      intraventricular hemorrhage (IVH) and cerebral palsy. Currently available options to treat a
      PDA include indomethacin, ibuprofen or acetaminophen followed by surgical or interventional
      closure of the PDA if medical therapy fails.

      Wide variation exists in PDA treatment practices across Canada. A survey conducted through
      the Canadian Neonatal Network (CNN) in 2019 showed that the most common choice of initial
      pharmacotherapy is standard dose ibuprofen. In view of the high pharmacotherapy failure rate
      with standard dose ibuprofen, there is a growing use of higher doses of ibuprofen with
      increasing postnatal age (with 32% of respondents currently adopting this practice) in spite
      of the fact that effectiveness and safety of higher ibuprofen doses have not been established
      in extremely preterm infants [&lt;29 weeks gestational age (GA)]. In view of this large practice
      variation across Canadian neonatal intensive care units (NICUs), we are planning a
      comparative effectiveness study of the different primary pharmacotherapeutic agents used to
      treat the PDA in preterm infants.

      Aims Primary: To compare the primary pharmacotherapeutic practices for PDA closure and
      evaluate their impact on clinical outcomes in extremely preterm infants (&lt;29 weeks GA)
      Secondary: To understand the relevance of pharmacotherapeutic PDA treatment with respect to
      clinical outcomes in the real world.

      Methods:

      Participants: Extremely preterm infants (&lt;29 weeks gestational age) with an echocardiography
      confirmed PDA who will be treated according to attending team

      Interventions:

        1. Standard dose ibuprofen [10-5-5 regimen, i.e., 10mg/kg followed by 2 doses of 5mg/kg at
           24h intervals]

        2. Adjustable dose ibuprofen [10-5-5 regimen if treated within the first week. Higher doses
           of ibuprofen up to a 20-10-10 regimen if treated after the postnatal age cut-off for
           lower dose as per the local center policy]

        3. Intravenous indomethacin [0.1-0.3mg/kg every 12-24h for a total of 3 doses].

        4. Acetaminophen [Oral/intravenous] (15mg/kg every 6h) for 3-7 days

      Outcomes:

      Primary: Failure of primary pharmacotherapy (Need for further medical and/or
      surgical/interventional treatment following an initial course of pharmacotherapy).

      Secondary: (a) Receipt of 2nd course of pharmacotherapy; (b) Surgical/interventional PDA
      closure; (c) CLD (d) NEC (stage 2 or greater) (e) Severe IVH (Grade III-IV) (f) Definite
      sepsis (g) Stage 1 or greater AKI; (h) Post-treatment serum bilirubin; (i) Phototherapy
      duration; (j) All-cause mortality during hospital stay.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, we intend to generate real-world evidence (RWE) by analyzing real‚Äêworld data
      (RWD) (defined as data generated during routine clinical practice) from a registry-based
      Comparative Effectiveness Research study.

      The Canadian Neonatal Network (CNN) is a well-established patient registry that includes
      members from 31 hospitals and 17 universities across Canada. The Network maintains a
      standardized NICU database and provides a unique opportunity for researchers to participate
      in collaborative projects. We will use the principles of Hypotheses Evaluating Treatment
      Effectiveness (HETE) research, which are designed to evaluate the presence or absence of a
      pre-specified effect and/or its magnitude. The network has recent experience in conducting
      such a study where one CIHR-funded study to evaluate effectiveness of two modes of
      non-invasive ventilation in preterm infants is already underway in 20 NICUs across Canada.

      The CNN's coordinating facility is located within the Maternal-Infant Care (MiCare) Research
      Center, Lunenfeld-Tanenbaum Research Institute (LTRI) at Mount Sinai Hospital (Toronto). Each
      participating site has highly trained abstractors who enter data from patient charts into the
      CNN database. The abstractors will also enter data specific to our project, which will allow
      us to obtain real-world data at a minimal cost with easy access to investigators for
      troubleshooting.

      Statistical Analysis overview: Since the proposed study is a CER using RWD, we will examine
      and account for potential confounders at the analyses stage. As recommended for HETE studies
      using RWD, accuracy of results will be checked by performing complementary sensitivity
      analyses. The analyses will be conducted in 2 stages: unit-level protocol effectiveness
      analysis and a secondary drug-dosage effectiveness analysis.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>20 Weeks</target_duration>
  <primary_outcome>
    <measure>Failure of primary pharmacotherapy</measure>
    <time_frame>through hospital discharge (approximately 20 weeks postnatal age unless death occurs first)</time_frame>
    <description>Receipt of further medical and/or surgical/interventional treatment following an initial course of pharmacotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Receipt of 2nd course of pharmacotherapy</measure>
    <time_frame>through hospital discharge (approximately 20 weeks postnatal age unless death occurs first)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical/interventional PDA closure</measure>
    <time_frame>through hospital discharge (approximately 20 weeks postnatal age unless death occurs first)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic lung disease</measure>
    <time_frame>birth through 36 weeks post menstrual age</time_frame>
    <description>Oxygen or respiratory support requirement at 36 weeks' postmenstrual age or at discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Necrotizing enterocolitis</measure>
    <time_frame>through hospital discharge (approximately 20 weeks postnatal age unless death occurs first)</time_frame>
    <description>Stage 2 or greater as per Bell's criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe intraventricular hemorrhage</measure>
    <time_frame>through hospital discharge (approximately 20 weeks postnatal age unless death occurs first)</time_frame>
    <description>Grade III-IV according to Papile Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definite sepsis</measure>
    <time_frame>through hospital discharge (approximately 20 weeks postnatal age unless death occurs first)</time_frame>
    <description>Clinical symptoms and signs of sepsis and a positive bacterial culture in a specimen obtained from normally sterile fluids or tissue obtained at postmortem</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Kidney Injury</measure>
    <time_frame>through hospital discharge (approximately 20 weeks postnatal age unless death occurs first)</time_frame>
    <description>Stage 1 or greater according to the Neonatal AKI KDIGO classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-treatment serum bilirubin</measure>
    <time_frame>within 7 days of initiation of pharmacotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum serum AST and ALT (u/L) during treatment or within 1 week of treatment completion</measure>
    <time_frame>within 7 days of completion of pharmacotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality during hospital stay</measure>
    <time_frame>through hospital discharge (approximately 20 weeks postnatal age unless death occurs first)</time_frame>
  </secondary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">1350</enrollment>
  <condition>Patent Ductus Arteriosus</condition>
  <condition>Extreme Prematurity</condition>
  <arm_group>
    <arm_group_label>Indomethacin Arm</arm_group_label>
    <description>Intravenous indomethacin at 0.1-0.3 mg/kg IV every 12-24h for a total of 3 doses as choice of initial pharmacotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard dose ibuprofen Arm</arm_group_label>
    <description>Standard dose ibuprofen [Oral/intravenous] at 10 mg/kg followed by 2 doses of 5mg/kg at 24 h intervals irrespective of postnatal age as choice of initial pharmacotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adjustable dose ibuprofen Arm</arm_group_label>
    <description>Adjustable dose ibuprofen [Oral/intravenous] as choice of initial pharmacotherapy. The dose of ibuprofen will be 10 mg/kg followed by 2 doses of 5 mg/kg at 24 h intervals if treated within the first 7 days after birth. Higher doses of ibuprofen up to 20 mg/kg followed by 2 doses of 10 mg/kg at 24 h intervals if treated after the postnatal age cut-off for lower dose as per the local center policy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acetaminophen Arm</arm_group_label>
    <description>Acetaminophen [Oral/intravenous] at 15mg/kg every 6h for 3-7 days as choice of initial pharmacotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Infants &lt;29 weeks GA with echocardiography-confirmed PDA but never received any pharmacotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference group</arm_group_label>
    <description>Infants &lt;29 weeks GA who were never diagnosed with PDA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indomethacin</intervention_name>
    <description>Intravenous formulation</description>
    <arm_group_label>Indomethacin Arm</arm_group_label>
    <other_name>indocid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>Intravenous and oral formulations</description>
    <arm_group_label>Adjustable dose ibuprofen Arm</arm_group_label>
    <arm_group_label>Standard dose ibuprofen Arm</arm_group_label>
    <other_name>Advil</other_name>
    <other_name>NeoProfen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>Intravenous and oral formulations</description>
    <arm_group_label>Acetaminophen Arm</arm_group_label>
    <other_name>paracetamol</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All infants born less than 29 weeks of gestation admitted to the participating sites will
        be included in the study. The population of interest will be those preterm infants &lt;29
        weeks gestational age (including outborns) with echocardiography confirmed PDA who will be
        treated according to attending team. Infants &lt;29 weeks GA with echocardiography-confirmed
        PDA but never received treatment will be included as the control population. Infants &lt;29
        weeks GA who were never diagnosed with PDA will be included as the reference population
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Extremely preterm infants (&lt;29 weeks gestational age) with an echocardiography
             confirmed PDA who will be treated according to attending team

        Exclusion Criteria:

          -  Any infant who received pharmacotherapy for a clinically symptomatic PDA without prior
             echocardiographic confirmation of the presence of PDA will be excluded from all
             analyses.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>12 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Souvik Mitra, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>IWK Health Center, Halifax, Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amish Jain, MBBS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mount Sinai Hospital, Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prakeshkumar Shah, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mount Sinai Hospital, Canada</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Souvik Mitra, MD, MSc</last_name>
    <phone>+1-902-470-6490</phone>
    <email>souvik.mitra@iwk.nshealth.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Foothills Medical Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Ayman Abou Mehrem</last_name>
    </contact>
    <contact_backup>
      <last_name>Amuchou Soraisham</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Royal Alexandra Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Abbas Hyderi</last_name>
    </contact>
    <contact_backup>
      <last_name>Kumar Kumaran</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Royal Columbian Hospital</name>
      <address>
        <city>New Westminster</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Miroslav Stavel</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>British Columbia Women's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Joseph Ting</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Victoria General Hospital</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Richard Taylor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Health Sciences Centre</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Deepak Louis</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Boniface General Hospital</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Ruben Alvaro</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Moncton Hospital</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Roderick Canning</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint John Regional Hospital</name>
      <address>
        <city>Saint John</city>
        <state>New Brunswick</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Luis Monterrosa</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IWK Health Center</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3K 6R8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Souvik Mitra</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kingston Health Sciences Centre</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Faiza Khurshid</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Soume Bhattacharya</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Eastern Ontario</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Nadya Ben Fadel</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Bonny Jasani</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Prakeshkumar Shah</last_name>
    </contact>
    <contact_backup>
      <last_name>Amish Jain</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Dany Weisz</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Windsor Regional Hospital</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Mohammad Adie</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Sainte-Justine</name>
      <address>
        <city>Montr√©al</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Anie Lapointe</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Quebec</name>
      <address>
        <city>Qu√©bec City</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Christine Drolet</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Edith Masse</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regina General Hospital</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Jayalakshmi Bodani</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal University Hospital</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Asma Nosherwan</last_name>
    </contact>
    <contact_backup>
      <last_name>Sibasis Daspal</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=410247&amp;lang=en</url>
    <description>Project funding information on the Canadian Institutes of Health Research (CIHR) Funding Decision Database</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 12, 2020</study_first_submitted>
  <study_first_submitted_qc>April 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2020</study_first_posted>
  <last_update_submitted>April 14, 2020</last_update_submitted>
  <last_update_submitted_qc>April 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IWK Health Centre</investigator_affiliation>
    <investigator_full_name>Dr. Souvik Mitra</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>indomethacin</keyword>
  <keyword>ibuprofen</keyword>
  <keyword>acetaminophen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ductus Arteriosus, Patent</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Indomethacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

